References
- Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: report of a prospective phase II study.2008:: 207-14.
- Nordlinger B., Sorbye H., B. Glimelius, Poston G.J. Peri-operative FOLFOX4 chemoterapy and surgery for resectable liver metastases from colorectal cancer.2008;: 963-5.
- Malafosse R, Penna C, Cunha AS, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies.2001;: 887-94.
- Folprecht G, Grothey A, Alberts S, Raab H-R, Köhne C-H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.2005,: 1311-9.
- van Cutsem E, Bodoky G, Roh JK, Folprecht G, Park YS, van Laethem JL, et al. ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC). [Abstract O-3001]. ECCO 14 Abstract Book.2007;(): 235.
- Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. The CRYSTAL study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first-line treatment with cetuximab or cetuximab plus FOLFIRI. [Abstract O-031].2008;(): vi17-8.
- Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, et al. Resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.2007;: 4593-602.
- Folprecht G, Gruenberger T, Hartmann JT, Lordick F, Stoehlmacher J, Bechstein W, et al. Randomized multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CELIM-Study). [Abstract 510PD]. ESMO 2008.2008;(): viii168.
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan fluorouracil and leucovorin for metastatic colorectal cancer.2004;: 2335-42.
- Salzt LB, Clarke S, Rubio ED, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with Oxaliplatin based chemotherapy as first line treatment in metastatic colorectal cancer: a randomized phase III study.2008;: 2013-9.
- Booth C. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm. [Correspondence].2008;: 4693-4.
- Saltz LB, Ahmad SA, Vauthey JN. Colorectal cancer: management of advanced disease. In: Kelsen DP, Daly MJ, Keren SE, Levin B, Tepper JE, editors.Philadelphia: Lippincott William & Wilkins; 2002. p. 825-52.
- Meta-analysis group in cancer. The efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.1998;: 301-8.
- Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study.2004;: 229-37.
- Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of itinotecan plus supporative care versus supporative care alone after fluorouracil failure for patients with metastatic colorectal cancer.1998;: 1413-8.
- Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group.2000;: 905-14.
- Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial.2000;: 1041-7.
- de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorine and fluorouracil with and without oxaliplatin as firstline treatment in advanced colorectal cancer.2000;: 2938-47.
- Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 crčme.2008:: 215-24.
- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.2004;: 337-74.
- Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.2008;: 5335-43.
- De Cerqueira Mathias C, Perazzo F, Simon S, Fein L4, Hidalgo J5, Murad A, et al. Cetuximab plus irinotecan in heavily-pretreated patients with mCRC: preliminary data from the LABEL study. [Abstract P-0159].2007;(): vii72.
- Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al. Cetuximab for the treatment of colorectal cancer. (NCIC CTG CO.17).2007;: 2040-8.
- Sobrero A, Hochster H, Luppi G, Kroening H4, Mulkerin D5, Chan A, et al. Cetuximab plus irinotecan in patients with mCRC who have failed prior oxaliplatin-based therapy: the EPIC trial. [Abstract O-0030].2007;(): Vii20.
- Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.2007;(12): 1539-44.
- Saltz L. In reply. [Correspondence].2008;: 4694-5.
- Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).2008;: 5326-34.
Language: English
Page range: 1 - 8
Published on: Mar 20, 2009
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2009 Janja Ocvirk, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.